Chronic Hepatitis B Drug Development Summit

5-6 Mai 2021

Pietro Scalfaro, notre directeur médical, présentera des résultats d’essais cliniques de notre composé principal Vonafexor au congrès “Chronic Hepatitis B Drug Development Summit” : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.

“This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection & mitigate related conditions such as fibrosis, cirrhosis, & hepatocellular carcinoma.”

Plus de détails ici : https://chronic-hbv-summit.com/

À lire dans 'Événements'